Estimating the Cost of Nosocomial Candidemia in the United States
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Sir—Candida species are the fourth most common cause of bloodstream infections in the United States [1] and are associated with an attributable mortality of up to 38% [2]. Recent estimates published in this journal suggest that each case of nosocomial candidemia results in excess costs of $34,123 per Medicare patient and $44,536 per private insurance patient, with national costs of nosocomial candidemia exceeding $200 million per year in the United States [3]. However, since that report was generated, our understanding of the epidemiology of nosocomial candidemia has significantly improved. In the recent report estimating national costs of nosocomial candidemia, an incident case of candidemia was identified through International Classification of Diseases, 9th revision (ICD-9), discharge diagnoses listed in the Nationwide Inpatient Sample (NIS) database [3]. Until that time, this method was the best mechanism for estimation of incidence, since population-based estimates of candidemia were lacking. One limitation of ICD-9 codes is that they have been developed for billing purposes, and billing personnel typically use no more than 15 ICD-9 codes for a given hospitalization. Other investigators have found that identifying incident cases of infection by this method can result in underestimation [4]. Potential for underestimation may be especially pertinent when patients generate numerous diagnoses during a complicated hospitalization, as is the case with many patients with nosocomially acquired candidemia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Overall attributable costs are difficult to calculate with precision, but have been estimated to be close to 1 billion dollars in the United States annually.21”
From Fungal Sepsis: Optimizing Antifungal Therapy in the Critical Care Setting (2011) · cites this paper as [21]
In the citing paper
“however, it should be noted that persistent fungemia with C. parapsilosis has been observed in the face of caspofungin therapy (163).”
From Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem (2007) · cites this paper as [163]
Citations
Cites
Nosocomial Bloodstream Infections in United States Hospitals: A Three‐Year Analysis
Edmond, M. B., Wallace, S. E., McClish, D. K., Pfaller, M. A., Jones, R. N., & Wenzel, R. P. (1999) · Clinical Infectious Diseases · doi:10.1086/520192 · Cited by 1,387
Hospital-Acquired Candidemia: The Attributable Mortality and Excess Length of Stay
Wey, S. B. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380120094019 · Cited by 831
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Self-citationThe Impact of Candidemia on Length of Hospital Stay, Outcome, and Overall Cost of Illness
Rentz, A. M., Halpern, M. T., & Bowden, R. (1998) · Clinical Infectious Diseases · doi:10.1086/514955 · Cited by 310
Guevara, R. E., Butler, J. C., Marston, B. J., Plouffe, J. F., File, T. M., & Breiman, R. F. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009804 · Cited by 140
Acalculous Cholecystitis Associated withPlasmodium falciparumInfection
Dylewski, J. S., & Al‐Azragi, T. (1999) · Clinical Infectious Diseases · doi:10.1086/520474 · Cited by 20
Acalculous Cholecystitis Associated with Plasmodium falciparum Malaria
Sanchez, R., Portilla, J., Boix, V., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/313944 · Cited by 18
Cited by
Items 101–110 of 110
Thompson, N. D. (2005) · OhioLink ETD Center (Ohio Library and Information Network)
Emerging Resistance Among Candida Species: Trends and Treatment Considerations for Candidemia
Lee, I., & Zaoutis, T. E. (2007) · Infectious disease and therapy · doi:10.3109/9781420017236.012
Sun, N. (2013) · DigitalGeorgetown (Georgetown University Library)
Glory, R., & Amandeep, K. (2016) · Spectrum Research Repository (Concordia University)
Lee, E. K. S. (2017) · Libraries and Cultural Resources (University of Calgary) · doi:10.11575/prism/28068
Initial Studies on the Lytic Effects of Burkholdines upon Mycotic Agents
Falkinham, J. O. (2017) · Journal of Bacteriology & Mycology Open Access · doi:10.15406/jbmoa.2017.05.00126
Luna, A. (2016) · doi:10.21007/etd.cghs.2016.0417
“The annual economic burden for this type of infection is estimated to exceed one billion dollars (41).”
BackgroundVaccines and Passive Immunity against Candidiasis
Spellberg, B. J., Fu, Y., & Ibrahim, A. S. (2014) · ASM Press eBooks · doi:10.1128/9781555817176.ch12
Reitler, P., Regan, J., DeJarnette, C. A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.13.580133
Vieillemard, A. (2011) · theses.fr (ABES) · doi:10.70675/c6929626z7565z4b2czb5c8zb5dde42e0d87 · Cited by 1
Metadata
- Authors
- Miller, L. G., Hajjeh, R. A., & Edwards, J. E.
- Affiliations
- University of California, Los Angeles (US)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Miller, L. G.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-04-01
- Volume
- 32
- Issue
- 7
- Pages
- 1110-1110
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2153953877
- Cited by
- 109
- References
- 7
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 7 · 2016: 7 · 2015: 7 · 2014: 9 · 2013: 10 · 2012: 6
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Infectious Diseases › Infection Control in Healthcare
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- nosocomial candidemia, candidemia, health care costs, cost estimation, National Inpatient Sample, incidence estimation, Medicare, private insurance, hospitalization
- MeSH terms
- Candidiasis, Humans, United States, Fungemia, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.